Literature DB >> 30919898

Long-term outcomes of patients undergoing tricuspid valve surgery†.

Nishant Saran1, Joseph A Dearani1, Sameh M Said2, Kevin L Greason1, Alberto Pochettino1, John M Stulak1, Simon Maltais3, Sertac Cicek1, Juan Crestanello1, Richard C Daly1, Katherine S King4, Hartzell V Schaff1.   

Abstract

OBJECTIVES: Limited literature is available on the best management strategy for tricuspid valve (TV) disease in adults. We sought to review our long-term outcomes of TV surgery with regard to survival and reoperation.
METHODS: A retrospective analysis of all patients ≥18 years of age [n = 2541, aged 67 ± 13years, 1433 (56%) females] who underwent first-time TV surgery between January 1993 and December 2013 was done. There were 1735 patients who received TV repair and 806 patients underwent replacement. A gradient boosting machine model was used to derive a propensity score for predicting replacement using 27 preoperative characteristics. Four hundred and eighteen propensity-matched pairs of TV repair and replacement were identified. Cox proportional hazard regression was used on the matched subset to determine the effect of replacement.
RESULTS: Functional TV regurgitation was present in 54% (n = 1369). A bioprosthesis was used in 84% (n = 680) of replacements, while 54% (n = 934) of TV repairs were ring annuloplasties. Operative mortality was 8% (n = 212). Overall survival was 54%, 29% and 13% at 5, 10 and 15 years, respectively. After propensity score matching, replacement was significantly associated with increased mortality [hazard ratio (HR) 1.54, 95% confidence interval (CI) 1.18-2.00; P = 0.001]. The cumulative incidence of TV reoperation was similar between the 2 groups when accounting for the competing risk of death [Fine-Gray HR 1.56, 95% CI 0.9-2.8; P = 0.144].
CONCLUSIONS: TV surgery is associated with poor outcomes due to multiple patient comorbidities. TV repair results in better survival compared to replacement in patients with similar comorbidities with no increased risk of getting a reoperation.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Propensity-matched analysis; Tricuspid valve ; Tricuspid valve repair ; Tricuspid valve replacement

Year:  2019        PMID: 30919898     DOI: 10.1093/ejcts/ezz081

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

1.  Early surgery can improve the outcomes of patients with severe tricuspid regurgitation undergoing tricuspid replacement.

Authors:  Kun Hua; Rui Zhao; Zhan Peng; Yunxiao Yang; Osmanaj Florian; Bin Mao; Xiubin Yang
Journal:  Cardiovasc Diagn Ther       Date:  2021-10

2.  Observed versus predicted mortality after isolated tricuspid valve surgery.

Authors:  Marco Russo; Guglielmo Saitto; Antonio Lio; Michele Di Mauro; Paolo Berretta; Maurizio Taramasso; Roberto Scrofani; Alessandro Della Corte; Sandro Sponga; Ernesto Greco; Matteo Saccocci; Antonio Calafiore; Giacomo Bianchi; Andrea Biondi; Irene Binaco; Ester Della Ratta; Ugolino Livi; Paul Werner; Carlo De Vincentiis; Federico Ranocchi; Marco Di Eusanio; Alfred Kocher; Carlo Antona; Fabio Miraldi; Giovanni Troise; Marco Solinas; Francesco Maisano; Guenther Laufer; Francesco Musumeci; Martin Andreas
Journal:  J Card Surg       Date:  2022-04-06       Impact factor: 1.778

Review 3.  Transcatheter and surgical treatment of tricuspid regurgitation: Predicting right ventricular decompensation and favorable responders.

Authors:  Alessandra Sala; Alessandro Beneduce; Francesco Maisano
Journal:  Front Cardiovasc Med       Date:  2022-09-27

4.  Late Outcomes of Valve Repair Versus Replacement in Isolated and Concomitant Tricuspid Valve Surgery: A Nationwide Cohort Study.

Authors:  Wang-Kin Wong; Shao-Wei Chen; An-Hsun Chou; Hsiu-An Lee; Yu-Ting Cheng; Feng-Chun Tsai; Kuang-Tso Lee; Victor Chien-Chia Wu; Chun-Li Wang; Shang-Hung Chang; Pao-Hsien Chu
Journal:  J Am Heart Assoc       Date:  2020-04-17       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.